Who is sponsoring NCT06482853?

NCT06482853 is sponsored by Milton S. Hershey Medical Center.

What condition does NCT06482853 study?

NCT06482853 studies Obesity, Hypertension.

What drugs are being tested in NCT06482853?

Interventions: Angiotensin-(1-7), Saline.

What is the status of NCT06482853?

NCT06482853 is currently RECRUITING.

Last reviewed 2025-09-18 · How we verify

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

NCT06482853 EARLY_PHASE1 RECRUITING

Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.

Details

Lead sponsor	Milton S. Hershey Medical Center
Phase	EARLY_PHASE1
Status	RECRUITING
Enrolment	52
Start date	2025-01-23
Completion	2029-03

Conditions

Obesity
Hypertension

Interventions

Angiotensin-(1-7)
Saline

Primary outcomes

Change in Muscle Sympathetic Nerve Burst Rate — 120 minutes
Muscle sympathetic nerve burst rate will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.
Change in Brachial Artery Diameter — 120 minutes
A blood pressure cuff will be inflated to a suprasystolic pressure for 5 minutes then deflated. Brachial artery diameter will be measured continuously before, during, and after cuff inflation using duplex ultrasound at baseline and at the end of angiotensin-(1-7) versus saline infusion.

Countries

United States